Drug Profile
DCR MYC
Alternative Names: DCR-M1711; DCR-MYCLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Dicerna Pharmaceuticals
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Proto oncogene protein c-myc inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours
Most Recent Events
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
- 03 Aug 2017 Dicerna Pharmaceuticals terminates a phase I trial in Non-Hodgkin's lymphoma, Solid tumours and Multiple myeloma (Second-line therapy or greater) due to sponsor decision in USA (IV) (NCT02110563)
- 03 Aug 2017 Dicerna Pharmaceuticals terminates a phase-I/II clinical trial due to sponsor decision in liver cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA, Singapore and South Korea (IV) (NCT02314052)